TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05776459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC102 gel
Description: Drug: AC102 Single intratympanic injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Active comparator: Prednisolone Tablets taken daily by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Tablets
Description: Placebo Tablets taken daily by mouth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo gel
Description: Placebo Single intratympanic injection
Study: NCT05543720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medly
Description: Medly will enable patients with HF, COPD, Hypertension, Mental Health, or Diabetes to input measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
Study: NCT05710458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25 gauge 20,000 cpm Hypervit Dual Blade
Description: Vitrectomy blade with increased cutting rate to 20,000 cut/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25 gauge 10,000 cpm Ultravit Vitrectomy Cutter
Description: Existing Vitrectomy blade with cutting rate 10,000 cut/min
Study: NCT05109104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP UnScented
Description: Sunscreen lip balm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP Herbal Mint
Description: Sunscreen lip balm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP Mountain Berry
Description: Sunscreen lip balm.
Study: NCT05823506

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PDE5 inhibitor (tadalafil) and BTL-6000 fSWT
Description: The mechanism of low-intensity shockwave therapy in patients with ED based on the effect on the endothelium of the cavernous arteries, the release of NO and the enhancement of vascularization due to release of angiogenic factors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDE5 inhibitor (tadalafil)
Description: Tadalafil improves erectile function by inhibiting PDE5 isoenzyme, thereby blocking cGMP degradation. As a result, the PDE5 inhibitors act synergistically with NO to markedly increase the levels of cGMP, which in the presence of sexual stimulation, lead to an erection. In the absence of sexual stimulation, NO is not released locally and the PDE5 inhibitors do not affect the penis. Thus, sexual stimulation is needed to initiate the erectile mechanism for the PDE5 inhibitors to take effect.
Study: NCT05109104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPF Standard Sunscreen
Description: SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
Study: NCT05965167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP05
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP05
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP05
Description: Oral tablets
Study: NCT05823506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PDE5 inhibitor (tadalafil)
Description: Tadalafil improves erectile function by inhibiting PDE5 isoenzyme, thereby blocking cGMP degradation. As a result, the PDE5 inhibitors act synergistically with NO to markedly increase the levels of cGMP, which in the presence of sexual stimulation, lead to an erection. In the absence of sexual stimulation, NO is not released locally and the PDE5 inhibitors do not affect the penis. Thus, sexual stimulation is needed to initiate the erectile mechanism for the PDE5 inhibitors to take effect.
Study: NCT04704661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceralasertib
Description: Given PO
Study: NCT05965167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forteo 20 mg
Description: Subcutaneous injection
Study: NCT04704661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Given IV
Study: NCT05517265

Intervention type: DRUG
Intervention: Calquence
Description: acalabrutinib (+/- obinutuzumab) according to Calquence® SmPC.
Study: NCT05965167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP11
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP11
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP11
Description: Oral tablets
Study: NCT05517265

Intervention type: DRUG
Intervention: Calquence
Description: acalabrutinib according to Calquence® SmPC.
Study: NCT06477042

Intervention type: OTHER
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score
Description: Change in quality-of-life score assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) between the 2-month early visit and inclusion in the poor-prognosis group.

Intervention type: OTHER
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ-12) score
Description: Change in quality-of-life score assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) between the 2-month early visit and inclusion in the poor-prognosis group.
Study: NCT03760315

Intervention type: DIAGNOSTIC_TEST
Intervention: blood mNGS (IDSeqTM Ultra); blood Culture
Description: take blood samples for mNGS and Culture at the same time in sepsis patients. No intervention on the treatment of the patients.
Study: NCT05248464

Intervention type: OTHER
Intervention: The Patient Dignity Inventory instrument (PDI)
Description: The PDI is an instrument made up of 25 items integrated into 5 factors that include: symptoms, existential anguish, dependency, peace of mind, and social support, prior to its application, adaptation, and validation will performer

Intervention type: OTHER
Intervention: WHOQOL-BREF (quality of life) instrument
Description: The WHOQOL-BREF is a self-report questionnaire which assesses 4 domains of quality of life (QOL): physical health, psychological health, social relationships, and environment, it consists of 24 items.
Study: NCT04881162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOVIS Transcarotid Neuroprotection System (NPS)
Description: The NOVIS Transcarotid Neuroprotection System (NPS) is intended to provide transcarotid vascular access and embolic protection
Study: NCT05954962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 200 MG
Description: The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of antagonist (ganirelix) subcutaneaous injections from day 5-6 of stimulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix Acetate
Description: The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.
Study: NCT04868474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training program and decision aid
Description: 1) a one-time, in-person, 2.5-hour training program encouraging participating GPs to present quitting smoking with a quit aid as the default choice to their eligible patients, and 2) access to an electronic decision aid that presents available quit aids. The 2.5-hour training program consists of: 1.5 hours of didactic teaching, with information about pharmacologic quit aids, electronic cigarettes, presenting quitting as a default choice, the decision aid, and a video of a model consultation. This is followed by 1 hour of role plays to practice presenting quitting as a default choice using the decision aid.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Refresher course
Description: A 45-minute refresher training about smoking cessation that does not aim to change GP behaviour. It will include the same information about pharmacologic quit aids and electronic cigarettes.
Study: NCT05321628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Cognitive Behavioural Therapy (iCBT) with Decision Support Tool
Description: Cognitive Behavioural Therapy för depression, panic disorder and social anxiety delivered thru texts and home works assignments via an internet platform with therapist weekly support through text messages. Therapist use a traditional, detailed therapist manual with the additions of a Clinical Decision Support Tool (DST) that identifies patients at risk of treatment failure and give suggestions to the therapist on how to act in relation to the specific patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based Cognitive Behavioural Therapy (iCBT)
Description: iCBT, as described above, using only the traditional, detailed therapist manual.
Study: NCT04947553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05 (dextromethorphan-bupropion)
Description: AXS-05 tablets, taken twice daily
Study: NCT05778630

Intervention type: OTHER
Group type: OTHER
Intervention: Focus group meetings
Description: Focus group meetings with different experts in the domain of CPCs (health care professionals) and/or parents or family members of a child with CPC. Focus group meetings will be facilitated by one or two study investigators. Group discussions will be audio-recorded.

Intervention type: OTHER
Group type: OTHER
Intervention: Focus group meetings
Description: Focus group meetings with different experts in the domain of CPCs (health care professionals) and/or parents or family members of a child with CPC. Focus group meetings will be facilitated by one or two study investigators. Group discussions will be audio-recorded.

Intervention type: OTHER
Group type: OTHER
Intervention: Individual interviews
Description: Individual qualitative interviews (semi-directive), conducted by one or two study facilitators.

Intervention type: OTHER
Group type: OTHER
Intervention: Individual interviews
Description: Individual qualitative interviews (semi-directive), conducted by one or two study facilitators.
Study: NCT04947553

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, taken twice daily
Study: NCT05266196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seclidemstat
Description: Treatment assigned as per parent protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seclidemstat
Description: Treatment assigned as per parent protocol
Study: NCT05103033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach for Mental Health (SAIA-MH)
Description: The 5 steps of SAIA-MH include: (1) cascade analysis to visualize treatment cascade drop-offs and prioritize areas for system improvements; (2) process mapping to identify modifiable facility-level bottlenecks; (3) identification and implementation of modifications to improve system performance; (4) assessment of modification effects on the cascade; and (5) repeated analysis and improvement cycles.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attentional Placebo Control
Description: Facilities randomized to attentional placebo control will attend a 1-week in-person training which will include the same minimum staff above for SAIA-MH. This training will focus on reviewing data collection tools, ethics, mental health stigma and burnout for mental health professionals. Following the 1-week in person training, attentional placebo control facilities will receive regular supervision following the same schedule as SAIA-MH focused on reviewing data collection tools.
Study: NCT05965167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP11
Description: Oral tablets
Study: NCT05662358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 1 ml (60 mg) of denosumab (Prolia; Amgen, Inc) subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: oral 70 mg alendronate sodium weekly plus subcutaneous placebo per 6 month.
Study: NCT05965167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP11
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP11
Description: Oral tablets
Study: NCT05605093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shionogi Protease Inhibitor (S-217622)
Description: S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.
Study: NCT06122610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
Description: SPECT/CT will be performed after first cycle of Lutathera® treatment
Study: NCT05965167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP11
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP22
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP22
Description: Oral tablets
Study: NCT05662358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral placebo weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: oral placebo weekly
Study: NCT06122610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photon Emission Tomography / CT (PET/CT)
Description: PET/CT will be performed after 64Cu-DOTATATE and Lutathera® treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-Dotatate
Description: Standard of care administration of radioactive drug for PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate
Description: Standard of care administration of radioactive drug for PET/CT and SPECT/CT
Study: NCT05965167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP22
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP22
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP22
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBP22
Description: Oral tablets
Study: NCT06479863

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Pozelimab/Cemdisiran
Description: Patients to receive Pozelimab 200mg/Cemdisiran 200 mg SC injections every 4 weeks for 104 weeks
Study: NCT05720520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technological education method
Description: Students in the experimental group will play the mobile application developed for stoma and peristomal skin care and are expected to learn the skill in this way. The students in the control group, on the other hand, will learn stoma and peristomal skin care on a model in the traditional skill laboratory and are expected to learn the skill in this way. Afterwards, the knowledge and skill scores of the two groups will be compared and the results will be reported.
Study: NCT05300737

Intervention type: OTHER
Intervention: intensive medical therapy
Description: Dual antiplatelet therapy, high potency statins, HTN control, lifestyle modification
Study: NCT06555640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR10624 Injection
Description: Drug: DR10624 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR10624 Injection
Description: Drug: DR10624 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR10624 Injection
Description: Drug: DR10624 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: placebo
Study: NCT06779773

Intervention type: DRUG
Intervention: Avacincaptad pegol (ACP)
Description: intravitreal injection
Study: NCT06780969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Green Mother Training
Description: Poster education
Study: NCT06781957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropins Subcutaneos
Description: Gonadotropins s.c. single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropins Subcutaneos
Description: Gonadotropins s.c. single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadotropins Subcutaneos
Description: Gonadotropins s.c. single dose
Study: NCT06781112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and tislelizumab ( 200mg).
Description: Induction chemotherapy with PD-1 inhibitor combined with TPF regimen, administered every 3 weeks: albumin paclitaxel (200mg/m2), cisplatin (60mg/m2, infused over 3 days), 5-fluorouracil (3000mg/m2, continuously intravenously pumped for 120 hours), and PD-1 inhibitor ( 200mg).~All patients received 3 cycles of induction therapy followed by radical concurrent chemoradiotherapy combined with tislelizumab (200mg) treatment, Q3W. The cisplatin in the synchronous chemoradiotherapy regimen is administered once a week, with a dose of 40mg/m2 per dose, and the total dose of cisplatin does not exceed 100mg/m2. For patients who cannot tolerate cisplatin during synchronous radiotherapy and chemotherapy, cisplatin may not be combined.
Study: NCT06782386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OneStep Foot Scanner
Description: Daily scans with the OneStep Foot scanner will provide thermal and visual data of the soles of the feet to assist in early identification of risk factors associated with Diabetic Foot Ulcers
Study: NCT06781086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Patients will receive 3 cycles of neoadjuvant treatment with Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant Nimotuzumab (400 mg on days 1, 8, and 15 of a 21-day cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG regimen
Description: Patients will receive 3 cycles of AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AG regimen
Description: Patients will receive 3 cycles of AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant AG (gemcitabine 1000 mg/m\^2 and nab-paclitaxel 125 mg/m\^2 on days 1 and 8 of a 21-day cycle).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 3 cycles of neoadjuvant treatment with placebo (400 mg on days 1, 8, and 15 of a 21-day cycle), followed by surgery and 5 cycles of adjuvant therapy (placebo 400 mg on days 1, 8, and 15 of a 21-day cycle).
Study: NCT06782048

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo by mouth once each day for a total of 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrvinium
Description: Participants will receive pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.
Study: NCT05064839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bony scintigraphy
Description: Bony scintigraphy (99mTc-Hydromethylene diphosphonate) will be performed in all patients with hypertrophy of the left ventricle
Study: NCT06782048

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood biomarkers analyses
Description: Up to 20ml of blood will be drawn from each participant at each study visit, with a total of 4 study visits for molecular analyses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood biomarkers analyses
Description: Up to 20ml of blood will be drawn from each participant at each study visit, with a total of 4 study visits for molecular analyses.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Oesophagogastroduodenoscopy (OGD) and biopsy
Description: Study participant will undergo OGD with collection of gastric mucosal biopsies at the baseline visit to ascertain IM status and for molecular analyses. Study participant will undergo follow-up gastroscopy with collection of gastric mucosal biopsies at day 7 of treatment, 6 weeks post-treatment and 1 year post-treatment to assess if endpoint is reached and for molecular analyses. Gastric juice samples will be collected during each OGD.
Study: NCT04825262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose based on CYP3A5 genotype
Study: NCT05703412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition-FOCUS mHealth Intervention
Description: tFOCUS integrates evidence-based strategies for self-management of severe mental illness (SMI) into a comprehensive mobile assessment and treatment system that is grounded in theoretical SMI models. The application promotes self-management strategies aimed at improving medication adherence to manage biologically driven psychiatric symptoms, increase social support to reduce the negative impact of social withdrawal, improve sleep hygiene to reduce levels of fatigue, and promote strategies for coping with persistent symptoms. tFOCUS application strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Check-In
Description: Check-in includes a discharge and safety plan (with medication instructions, crisis services, etc.), a timely follow-up appointment with a mental health provider, and phone check-ins by case managers immediately following post-discharge for care coordination purposes.
Study: NCT06555640

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: placebo